Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
| Revenue (TTM) | $22.48B |
| Gross Profit (TTM) | $10.55B |
| EBITDA | $6.12B |
| Operating Margin | 15.70% |
| Return on Equity | 6.61% |
| Return on Assets | 4.34% |
| Revenue/Share (TTM) | $79.76 |
| Book Value | $89.64 |
| Price-to-Book | 2.04 |
| Price-to-Sales (TTM) | 2.32 |
| EV/Revenue | 2.927 |
| EV/EBITDA | 13.37 |
| Quarterly Earnings Growth (YoY) | -31.40% |
| Quarterly Revenue Growth (YoY) | 5.40% |
| Shares Outstanding | $272.39M |
| Float | $271.67M |
| % Insiders | 0.43% |
| % Institutions | 99.76% |
Volatility is currently contracting
BDX's Revello stent shows strong nine-month AGILITY trial results, with high vessel patency and low failure rates, boosting its peripheral vascular prospects.
Most income investors chase flashy yields and overlook the quiet compounders that have raised their dividends through recessions, rate shocks, and global pandemics.
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
FRANKLIN LAKES, N.J., Oct. 8, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m.
Physicians, policymakers, and global health experts urge broader access to monitoring technologies that can help identify life-threatening complications earlier, helping more mothers survive childbirth and giving babies a healthier start in life. FRANKLIN LAKES, N.J.
BD plans a $19B U.S. investment, including $3B for manufacturing, to boost domestic medical consumables capacity and supply-chain resilience.
Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac artery disease. FRANKLIN LAKES, N.J.
Generations of Connecticut employees have helped ensure the reliable supply of the BD® Syringe, an essential medical device clinicians rely on every day in patient care around the world CANAAN, Conn., Oct. 6, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today marked 65 years of manufacturing in Canaan, Conn.
FRANKLIN LAKES, N.J., Oct. 6, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Ferass Abuzaina has been named worldwide president of the Surgery business unit at BD, effective immediately.
Agreement supports significant investments in U.S. manufacturing, strengthens healthcare resilience and increases domestic production of essential medical consumables used in approximately 90% of U.S. hospital visits FRANKLIN LAKES, N.J., Oct. 6, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), one of the world's leading medical technology companies and the nation's largest manufacturer of essential medical consumables, today announced a landmark partnership with the U.S. Government to expand domestic manufacturing and strengthen the resilience of supply chains for essential medical consumables relied on by clinicians and patients every day.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BDX and any ticker you trade — then tracks every position and per-strategy win rate.
